Another study reported satisfactory antitumor activity following crizotinib treatment for NSCLC with high levels of MET amplification (MET-to-CEP7 ratio ≥4, ORR: 38.1%) and for NSCLC with exon 14 skipping mutations (53). The gene discussed is MET; the disease is non-small cell lung carcinoma.